Main content

Board of directors

 

 

 

 

 

Jan H. Egberts

Chairperson of the Board

Dr. Egberts has over 25 years of experience in the pharmaceutical and medical devices sector. Currently, Dr Egberts serves as the Managing Partner of Veritas Investments, a private investment company focused on minority and controlling investments in healthcare companies.

Dr Egberts gained his medical degree from Erasmus University Medical School in the Netherlands and pursued the clinical part of his medical training at Harvard Medical School. Dr Egberts also obtained an MBA from Stanford University.

After Stanford, he joined McKinsey & Co. as a strategic consultant in New York. Dr Egberts subsequently held various business development and general management positions of increasing responsibility in the USA at Merck & Co. and Johnson & Johnson. Thereafter, he served as Senior Advisor, Healthcare Investments for 3i, the private equity firm. Dr Egberts then became CEO of OctoPlus, a publicly traded specialty pharmaceutical company in the Netherlands. OctoPlus was subsequently acquired by Dr Reddy Laboratories. After this, Dr Egberts joined Agendia, a molecular diagnostics company, initially as board member and subsequently full time as interim CEO. Dr Egberts also has held over 15 executive and non-executive supervisory board positions in the U.S.A. and various European countries.

Jan Egberts holds 0 shares in Photocure.

 

 

 

 

Johanna Holldack

Director

Dr. Holldack has international operational experience from pharma companies, including clinical trials, drug approvals, IPOs and licensing. She has also managed several mergers and acquisitions. In addition, Dr. Holldack has venture capital experience from Swiss-based Aravis Venture where she was a partner for 5 years.  Her industry career spans over 20 years, during which she held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene, Borean Pharma, Telormedix and Trethera Corporation. She is chairman of Amal Therapeutics.

Dr. Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified paediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School.

Johanna Holldack holds 0 shares in Photocure.

 

 

Gwen Melincoff

Director

Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management.

From 2014 to 2016, she served as Vice President of Business Development at BTG International Inc. From 2004 to the 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals. Additionally, she led the Strategic Investment Group (SIG), Shire’s $50MM corporate venture fund which was started in 2010.

Ms. Melincoff has a B.S in Biology, a Master’s of Science in Management, and has attained the designation of the Certified Licensing Professional (CLP™).

Gwen Melincoff holds 0 shares in Photocure.

  

Synne H. røine

Director

Synne H. Røine is CFO of Colosseum Smile Group, a leading provider of dental care in Scandinavia. Ms Røine has broad international experience in the biotech and specialty pharma. She served as CFO of Bionor Pharma ASA from 2013 to 2015, a biotechnology company working with therapeutic vaccines against viral diseases. From 2009 to 2013 she was CFO of Pronova BioPharma ASA, which develops and sells Omega-3 based pharmaceuticals. The company was in 2013 sold to BASF for NOK 5 billion. Ms Røine is a Board member of Navamedic ASA. Ms Røine holds a Master in Business and Economics from Université des Sciences Sociales Toulouse, France.

Synne Røine holds 0 shares in Photocure. She holds no share options in the company.

 

 

Tom Pike

Director

Tom Pike serves as Chairperson of Vaccibody, and has been associated with the pharmaceutical industry in Norway for many years. Previous positions includes Partner in the venture capital fund NeoMed, Chairperson & CEO of Clavis Pharma ASA as well as Chairperson of the Association of the Pharmaceutical Industry in Norway. He has worked at Hoffman-La Roche in Norway and Switzerland for 18 years, including 8 years as general manager in Norway. Mr Pike holds a B.Sc. Honours in Pharmacology.

Tom Pike holds 3 400 shares in Photocure. He holds no share options in the company.

 

 

 

 

Grannum R. Sant

Director

Grannum R. Sant is currently an independent consultant for medical organizations and biopharmaceutical industry, and Professor of Urology at Tufts University School of Medicine in Boston, USA. Dr. Sant has a broad and deep international experience in pharma and academia. From 2003 to 2013 he held senior leadership roles including Vice President and Head of Medical Affairs for urology and oncology at Sanofi US. His last pharma position (2010-2013) was as Vice President, Head of Global Medical Affairs Rare Genetic Diseases at Genzyme. Dr. Sant is a board certified urologist in the US and prior to 2003 was Professor and Chair of the Urology at Tufts University School of Medicine.

Grannum Sant holds no shares or share options in Photocure.

 

Xavier Yon

 Director

As a former President and CEO, Galderma
Xavier Yon has spent more than 40 years in the pharmaceutical industry. He has previously worked for Solvay, Pfizer and Alcon before starting as President and CEO of Galderma in 1989. Under Xavier Yon’s leadership Galderma grew into being the leading dermatology company globally. Since he retired from Galderma in 2004 he has been Managing Director of XY Consulting. He has broad international experience and has lived in Africa and USA in addition to France. He is board member of Virbac Aminal Health (France) and Graceway Pharmaceuticals (USA). Xavier Yon holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris and attended the Advanced Management Program at Harvard University.

Xavier Yon holds no shares or share options in Photocure.

 

<P class=contents>&nbsp;</P>
<TABLE border=0 width=492>
<TBODY>
<TR vAlign=top>
<TD>
<P>&nbsp;</P>
<P><IMG alt="" src="/upload/People/Åse Aulie Michelet_5.jpg" orgurl="/upload/People/Åse Aulie Michelet_5.jpg"></P></TD>
<TD>
<P><STRONG><FONT color=#3f5e72 size=2>Åse Auli Michelet, </FONT></STRONG>Chairman of the Board&nbsp;<BR><BR><SPAN style="FONT-FAMILY: 'Arial', 'sans-serif'; FONT-SIZE: 8.5pt"><FONT color=#000000>Åse Aulie Michelet, M.Sc. in </FONT><FONT color=#000000>Pharmacy, born 1952, was elected as a&nbsp;Director&nbsp;in Photocure in April 2010.&nbsp;She has previously served on the board of Photocure from 1996 to 2003.</FONT></SPAN><SPAN style="FONT-FAMILY: 'Arial', 'sans-serif'; FONT-SIZE: 8.5pt"><FONT color=#000000>&nbsp;<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office"/><o:p></o:p></FONT></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 'Arial', 'sans-serif'; FONT-SIZE: 8.5pt"><FONT color=#000000>Åse Aulie Michelet has&nbsp;a long and extensive experience&nbsp;from pharmaceutical industry&nbsp;within research, marketing and operations.&nbsp;After nearly 30 years with Nycomed, Amersham and&nbsp;GE&nbsp;Healthcare, her last position with GE Healthcare&nbsp; was as&nbsp;Executive Vice President for global operations&nbsp;in Medical Diagnostics and CEO for &nbsp;GE Healtcare AS. From 2008 to 2010 she was CEO for Marine Harvest ASA.&nbsp; Åse Aulie Michelet has served as a member of the Board of Directors of&nbsp;several public companies. She is a member of the Board of Orkla ASA.&nbsp;<o:p></o:p></FONT></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-SIZE: 8.5pt"><o:p><FONT color=#000000 face="Times New Roman">&nbsp;</FONT></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 6.7pt; mso-margin-top-alt: auto" class=MsoNormal><SPAN style="FONT-FAMILY: 'Arial', 'sans-serif'; FONT-SIZE: 8.5pt"><FONT color=#000000>Åse Aulie Michelet holds no shares or share options in Photocure.</FONT></SPAN></P>
<P style="MARGIN: 0cm 0cm 6.7pt; mso-margin-top-alt: auto" class=MsoNormal>&nbsp;</P></TD></TR>
<TR vAlign=top>
<TD>
<P>&nbsp;</P>
<P><IMG alt="" src="/upload/People/Jon_Hindar_smallthumb_web.jpg" orgurl="/upload/People/Jon_Hindar_smallthumb_web.jpg"></P></TD>
<TD>
<P><STRONG><FONT color=#3f5e72 size=2>Jon Hindar, </FONT></STRONG>Director<BR><BR>Jon Hindar, MSc., born 1957, was elected as a Director in Photocure in 2006. He is CEO of NorSun AS. Prior to joining NorSun, Mr. Hindar was Senior Vice President of the Life Sciences Division in Invitrogen. He was president and CEO of Dynal Biotech from 2002 until Invitrogen's acquisition of Dynal in April 2005. Mr. Hindar has 10 years experience in R&amp;D from various positions with Alcatel and BP Chemicals and another 10 years experience in various General Manager roles in the chemical industry. Before joining Dynal, Mr. Hindar was Managing Partner for five years at the Norwegian investment bank; Fondsfinans. Mr. Hindar is an alumni of IMD (Lausanne, Switzerland) where he joined the Executive Development program in 1993/94.</P>
<P>Mr Jon Hindar holds 8,000 shares in Photocure. He holds no share options in the company.</P>
<P>&nbsp;</P></TD></TR>
<TR vAlign=top>
<TD>
<P>&nbsp;</P>
<P><IMG alt="" src="/upload/People/Mats-Petterssonthumb.gif" orgurl="/upload/People/Mats-Petterssonthumb.gif"></P></TD>
<TD>
<P class=contents><STRONG><FONT color=#3f5e72 size=2>Mats Petterson</FONT></STRONG>, Director</P>
<P class=contents>Mats Petterson, B.Sc. in Economics and Business Administration, was elected as a Director of Photocure in April 2008.<BR>Mats Pettersson is a board member of H. Lundbeck A/S and deputy chairman of the board of SwedenBio AB. He is member of the board of Ablynx NV.<BR>Mats Pettersson joined Pharmacia in 1976, where he held the position of CFO and different business development positions. Before joining Biovitrum, he was Senior Vice President and member of the Management Committee of Pharmacia Corporation. Mats has been responsible for most of the major transforming mergers in Pharmacia over the last ten years and has spent more than 16 years abroad during his career.<BR></P>
<P class=contents>Mats Petterson&nbsp;holds no shares or share options in Photocure.</P>
<P class=contents>&nbsp;</P></TD></TR>
<TR vAlign=top>
<TD>
<P>&nbsp;</P>
<P><IMG alt="" src="/upload/People/Eva-Steinness-thumb.gif" orgurl="/upload/People/Eva-Steinness-thumb.gif"></P></TD>
<TD>
<P class=contents><STRONG><FONT color=#3f5e72 size=2>Eva Steiness</FONT></STRONG>, Director<BR><BR>Eva Steiness, MD, D.Sc.(medicine), Professor i Clinical Pharmacology, was elected as a Director in Photocure in April 2008.<BR>Eva Steiness has a long and extensive experience from development and registration of new drugs. She was responsible for R&amp;D and Regulatory Affairs in H. Lundbeck A/S from 1989 to 1998. She revitalized the R&amp;D activities completely and increased focus on the authorities expectations and at the same time marketing’s strategy and needs. The R&amp;D staff increased from 85 to 450 under her leadership, and the productivity and innovation power were very high.<BR>Eva Steiness founded Zealand Pharma A/S in 1998 based on 3 patent applications. She managed the company until 2007, inkluding development of an anti-diabetic compound out-licenced to Sanofi-Aventis.</P>
<P class=contents>Eva Steiness holds no shares or share options in Photocure.</P>
<P class=contents><BR>&nbsp;</P></TD></TR>
<TR vAlign=top>
<TD>
<P>&nbsp;</P>
<P><IMG alt="" src="/upload/People/IngridWiik-80pix.jpg" orgurl="/upload/People/IngridWiik-80pix.jpg"></P></TD>
<TD>
<P><STRONG><FONT color=#3f5e72 size=2>Ingrid Wiik</FONT></STRONG>, Director</P>
<P>(Born 1945),&nbsp; former President and CEO, Alpharma Inc.<BR>Ingrid Wiik has spent more than 30 years in the pharmaceutical industry, both in R&amp;D and general management, and has extensive leadership and international experience. She was President and CEO of Alpharma Inc. (listed on NYSE), a position she held from January 2000 until June 2006. Prior to this, Ingrid Wiik was Vice President and President of the International Pharmaceuticals Division at Alpharma (1994-1999). She currently holds several Board positions: Algeta ASA, Diagenic ASA, Coloplast AS (Denmark), Human Care (Sweden), Norske Skog ASA and Biotec Pharmacon ASA (Norway); and was previously on the Boards of Statoil ASA and Alpharma Inc.. Ingrid Wiik holds a Master of Pharmacy degree from the University of Oslo, a MSc degree (Biopharmacy) from University of London and a MBA from BI Norwegian Business School.</P>
<P>&nbsp;</P></TD></TR>
<TR vAlign=top>
<TD>
<P>&nbsp;</P>
<P><IMG alt="" src="/upload/People/XavierYon80pix.jpg" orgurl="/upload/People/XavierYon80pix.jpg"></P></TD>
<TD>
<P><STRONG><FONT color=#3f5e72 size=2>Xavier Yon</FONT></STRONG>, Director</P>
<P>(Born 1940), former President and CEO, Galderma<BR>Xavier Yon has spent more than 40 years in the pharmaceutical industry. He has previously worked for Solvay, Pfizer and Alcon before starting as President and CEO of Galderma in 1989. Under Xavier Yon’s leadership Galderma grew into being the leading dermatology company globally. Since he retired from Galderma in 2004 ha has been Managing Director of XY Consulting. He has broad international experience and has lived in Africa and USA in addition to France.</P>
<P>He is board member of Virbac Aminal Health (France) and Graceway Pharmaceuticals (USA). Xavier Yon holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris and attended the Advanced Management Program at Harvard University.</P>
<P>&nbsp;</P></TD></TR></TBODY></TABLE>